JP2014527969A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527969A5
JP2014527969A5 JP2014530945A JP2014530945A JP2014527969A5 JP 2014527969 A5 JP2014527969 A5 JP 2014527969A5 JP 2014530945 A JP2014530945 A JP 2014530945A JP 2014530945 A JP2014530945 A JP 2014530945A JP 2014527969 A5 JP2014527969 A5 JP 2014527969A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014530945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527969A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/055887 external-priority patent/WO2013043580A2/en
Publication of JP2014527969A publication Critical patent/JP2014527969A/ja
Publication of JP2014527969A5 publication Critical patent/JP2014527969A5/ja
Ceased legal-status Critical Current

Links

JP2014530945A 2011-09-19 2012-09-18 改変クレアチン化合物 Ceased JP2014527969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161536280P 2011-09-19 2011-09-19
US61/536,280 2011-09-19
PCT/US2012/055887 WO2013043580A2 (en) 2011-09-19 2012-09-18 Modified creatine compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017111480A Division JP2017160254A (ja) 2011-09-19 2017-06-06 改変クレアチン化合物

Publications (2)

Publication Number Publication Date
JP2014527969A JP2014527969A (ja) 2014-10-23
JP2014527969A5 true JP2014527969A5 (enExample) 2015-11-12

Family

ID=46982949

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014530945A Ceased JP2014527969A (ja) 2011-09-19 2012-09-18 改変クレアチン化合物
JP2017111480A Pending JP2017160254A (ja) 2011-09-19 2017-06-06 改変クレアチン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017111480A Pending JP2017160254A (ja) 2011-09-19 2017-06-06 改変クレアチン化合物

Country Status (8)

Country Link
US (1) US9434753B2 (enExample)
EP (1) EP2758411A2 (enExample)
JP (2) JP2014527969A (enExample)
CN (1) CN103889993B (enExample)
AU (1) AU2012312654B2 (enExample)
CA (1) CA2849073A1 (enExample)
HK (1) HK1200459A1 (enExample)
WO (1) WO2013043580A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20121098A1 (it) * 2012-12-18 2014-06-19 Univ Degli Studi Genova Procedimento per sintetizzare derivati della creatina
RU2015143130A (ru) 2013-03-15 2017-04-21 Дженсиа Корпорейшен Композиции и способы лечения состояний, поражающих эпидермис
US20160289175A1 (en) * 2013-11-05 2016-10-06 Ultragenyx Pharmaceutical Inc. Creatine analogs and the use thereof
US9617230B2 (en) * 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
TWI741979B (zh) 2015-03-30 2021-10-11 美商法明頓製藥發展公司 磷酸肌酸類似物前藥、其組成物及用途
US10883978B2 (en) * 2017-01-31 2021-01-05 Agilent Technologies, Inc. Method and device for calibration of biological flux
WO2019026610A1 (ja) * 2017-08-04 2019-02-07 学校法人 早稲田大学 微小空間の加温方法及び発熱体並びに微小空間の減温方法及び吸熱体
IL274701B2 (en) 2017-12-01 2024-07-01 Ultragenyx Pharmaceutical Inc Promote drugs, compositions and methods of their use
KR101920902B1 (ko) * 2017-12-27 2018-11-21 전남대학교 산학협력단 심혈관 질환 조기진단 pet 조영용 화합물 및 그의 용도
WO2021085906A1 (ko) * 2019-10-30 2021-05-06 주식회사 퓨전바이오텍 미토콘드리아 표적 화합물 및 이를 포함하는 노화 관련 질환의 치료 또는 예방을 위한 조성물
CN115417898B (zh) * 2022-08-02 2024-03-26 浙江工业大学 一种三苯基鏻单体化合物及其制备方法与在制备核酸递送纳米载体中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU4151996A (en) 1994-11-08 1996-05-31 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
US20060128671A1 (en) 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
EP1065931A4 (en) * 1998-04-02 2006-10-11 Avicena Group Inc COMPOSITIONS CONTAINING CREATINE COMBINED WITH A SECOND AGENT
DE69913712T2 (de) 1998-08-25 2004-10-07 Uab Res Foundation Birmingham Inhibitoren der bakteriellen nad synthetase
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
WO2005019232A1 (en) 2003-08-22 2005-03-03 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
MXPA01007760A (es) 1999-02-01 2003-06-24 Eisai Co Ltd Compuesto adyuvante inmunologico.
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US6355616B1 (en) * 1999-06-25 2002-03-12 Xoma (Us) Technology Ltd. Derivative compounds derived from or based on bactericidal/permeability-increasing protein
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
HUP0303074A3 (en) 2000-09-27 2007-08-28 Ajinomoto Kk Benzodiazepine derivatives and pharmaceutical compositions them
JP2005298343A (ja) 2002-03-27 2005-10-27 Ajinomoto Co Inc ベンゾジアゼピン誘導体
JP2003321499A (ja) 2002-04-30 2003-11-11 Internatl Reagents Corp ミトコンドリアクレアチンキナーゼ抗体
ES2436011T3 (es) * 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
CN1839142B (zh) * 2003-08-22 2010-06-16 澳新制药公司 用作靶向线粒体的抗氧化剂的线粒体醌衍生物
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
WO2006005759A2 (en) 2004-07-13 2006-01-19 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
US7915230B2 (en) 2005-05-17 2011-03-29 Molecular Transfer, Inc. Reagents for transfection of eukaryotic cells
US20070066572A1 (en) * 2005-09-14 2007-03-22 Kalyanaraman Balaraman Neuroprotection by positively-charged nitroxides
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
JP5364574B2 (ja) 2006-05-05 2013-12-11 モレキュラー、トランスファー、インコーポレイテッド 真核細胞のトランスフェクションのための新規試薬
AU2007300782B2 (en) * 2006-09-28 2013-08-29 United Kingdom Research And Innovation Triphenylphosphonium thionitrite nitric oxide donors
EP2197890A1 (en) * 2007-09-07 2010-06-23 Gencia Corporation Mitochondrial compositions and uses thereof
ATE551342T1 (de) 2008-02-22 2012-04-15 Irm Llc Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
WO2009111846A1 (en) 2008-03-14 2009-09-17 Stephen John Ralph Mitochondrially delivered anti-cancer compounds
WO2010126719A1 (en) * 2009-04-27 2010-11-04 Mcw Research Foundation, Inc. Neuroprotective compounds and their use
WO2011011366A2 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
US20130190244A1 (en) * 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections

Similar Documents

Publication Publication Date Title
MX2022005399A (es) Compuestos.
JP2008509166A5 (enExample)
JP2014043462A5 (enExample)
JP2008522981A5 (enExample)
JP2010509375A5 (enExample)
CY1118102T1 (el) Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων
MX377255B (es) Lipidos y composiciones de lipidos para el suministro de agentes activos.
JP2013530179A5 (enExample)
JP2019529518A5 (enExample)
Majer et al. Discovery of orally available prodrugs of the glutamate carboxypeptidase II (GCPII) inhibitor 2-phosphonomethylpentanedioic acid (2-PMPA)
AU2012312654B2 (en) Modified creatine compounds
CA2750413A1 (en) Hydroxamic acid derivatives
JP2017518304A5 (enExample)
JP2009544582A5 (enExample)
JP2015529228A5 (enExample)
EA202090514A1 (ru) Противовирусное средство против гепатита в
JP2018528273A5 (enExample)
JP2018530582A5 (enExample)
JP2012021006A5 (enExample)
JP2017537886A5 (enExample)
UA114405C2 (uk) Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу
RU2012135698A (ru) Способ и композиция
JP2009541225A5 (enExample)
JP2016028032A5 (enExample)
RU2016149761A (ru) Производные нуклеозидов для лечения ракового заболевания